Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences
04 oct. 2022 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea
30 août 2022 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company that focuses on the development and...
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
09 août 2022 16h01 HE
|
Journey Medical Corporation
Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional sites underway in Europe open to enrollment ...
Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022
03 août 2022 08h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity
24 mai 2022 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the...
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference
23 mai 2022 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
10 mai 2022 16h01 HE
|
Journey Medical Corporation
Generated record revenue of $23.3 million for the first quarter of 2022 First patient dosed in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea Company to hold...
Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022
03 mai 2022 16h15 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 03, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
04 avr. 2022 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., April 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
23 mars 2022 16h01 HE
|
Journey Medical Corporation
Generated record net product revenues of $63.1 million for the full year 2021 Completed initial public offering of common stock and raised $30.6 million in net proceeds Dosed first patient in Phase...